0532979-A2 is referenced by 1 patents.
Peptides having antigenic or immunogenic determinants are proposed which are recognised by autoantibodies, in particular in body fluids of patients who suffer from systemic lupus erythematosus (SLE). The two peptides are preferably the C-terminus of H1 containing the sequence section 187 - 211 and the N-termini of H2B containing the sequence sections 1 - 35 and 36 - 76 which exhibit cross-reactions with the autoantibodies (anti-histone antibodies). The invention additionally indicates routes for the formation of monoclonal antibodies and anti-idiotypic antibodies which are directed against the autoantibodies. The diagnosis of SLE can be carried out according to the invention with increased safety and the monoclonal antibodies directed against the autoantibodies are also suitable for the preparation of means for the therapy of SLE.